Prostate cancer specifically metastasizes to bone where it leads to bone formation. We previously reported that coculturing MDA PCa 2b prostate cancer cells with primary mouse osteoblasts (PMOs) induced PMO proliferation and differentiation. An osteoblastic reaction was also observed in vivo after injection of MDA PCa 2b cells into the bones of severe combined immunodeficient disease mice. The aim of this study was to identify the sequence of events that leads to these osteoblastic lesions in vivo and, using this in vitro model, to define the contributions of various genes and cellular pathways in the pathophysiology of osteoblastic bone metastases of prostate cancer.
Experimental Design and Results: We show histological evidence of de novo bone formation as early as 2 weeks after injection of MDA PCa 2b cells in the bone of severe combined immunodeficient disease mice. In vitro, we show that PMOs induce MDA PCa 2b proliferation, suggesting a synergistic paracrine loop between these cells and PMOs. Endothelin (ET)-1, which is a mitogen for several cell types, is produced by all prostate cancer cell lines tested, and Atrasentan, an antagonist of ET-1 receptor A, partially reversed PMO proliferation induced by MDA PCa 2b cells. ET-1 is known to be comitogenic with a number of growth factors, including insulin-like growth factor (IGF)-I. In this study, we report that IGF-binding protein (IGFBP)-3 transcripts (that regulate levels of free IGF) are down-regulated in prostate cancer cells cocultured with PMO, whereas prostate-specific antigen (a protease known to cleave IGFBP-3) is detected in the 150–400 ng/ml range. Accordingly, IGFBP-3 has antiproliferative effects in PMOs, which were attenuated in our in vitro system. Taken together, our studies also implicate the IGF axis to play a role in this model of bone metastases. Secondly, the transcript level of mouse double minute 2 (a protein that regulate p53) was increased in prostate cancer cells grown with PMOs. The p5
we knew many months ago that it does work...These shorts don't care about nothing but dollars any way they can get them .''even any false stories''
We should see a release by next week on this event,,,
Dear Mr. Price:
Thank you for your correspondence dated October 30, 2013, to the U.S. Securities and Exchange Commission (SEC).
We appreciate your alerting us to your concerns regarding Seeking Alpha and Sarepta Therapeutics. The SEC’s Office of Investor Education and Advocacy (OIEA) processes many complaints received from individual investors and others. We keep records of the correspondence we receive in a searchable database that SEC staff may make use of in inspections, examinations, and investigations. In addition, some correspondence received by OIEA is referred directly to other SEC offices and divisions for their review.
Thank You Elizabeth Warren – We are glad to have you on our team.
October 30, 2013 / Comments Off
Katie (Katherine) at the Jett Foundation was thrilled to receive this email today from Elizabeth Warren!! Momentum is building. This is another great step in our push for Accelerated Approval
Dear Katherine of Jett Foundation,
Thank you for contacting me to express your support for the accelerated approval of the drug eteplirsen, which has the potential to help a subset of boys with Duchenne Muscular Dystrophy (DMD), by the FDA.
DMD is a fatal genetic neurological disorder and is one of the several types of muscular dystrophy. According to the Center for Disease Prevention (CDC), it affects approximately one in 3,500 boys born in the country. More than 20,000 boys and young men are estimated to suffer from DMD. The disease is caused by a mutation in the gene that produces the protein dystrophin. Eteplirsen was made possible due to our understanding of the genetics of DMD, and I believe that our investments in research will continue to give us new targets and therapies for DMD.
I appreciate your views on this issue and recently sent a letter with my colleague Senator Ed Markey urging the FDA to consider the application for this drug. In addition, I strongly support increasing our government’s investment in scientific research to build the knowledge base necessary to advance medicine. For that reason, I supported an increase in funding during the appropriations process for the National Institutes of Health (NIH), our nation’s premier medical research agency and funder of academic medical research around the country. I will continue to fight alongside my Senate colleagues to provide research funding that will help lead to better insights and new treatments for those with DMD.
I appreciate your reaching out to me about this important issue, and I hope you contact my office again in the future about issues of importance to you or if I can be of assistance.
confirmatory trial for all the other exons.....................................................................
Currently ,no dmd treatment available .Sarepta's dmd drug works and scientific facts prove it will work on all.
Sarepta's dmd drug has no safety issues .No other treatments even close in the pipeline anywhere.
Common sense and good research data shows a outstanding clinical benefits .
Share price forecast SINCE APRIL WHEN POLLING BEGAN
The 12 analysts offering 12 month price targets for Sarepta Therapeutics Inc have a median target of 56.00, with a high estimate of 71.00 and a low estimate of 34.00. The median estimate represents a 49.25% increase from the last price of 37.52.
THAT IS STRANGE,MAYBE IT IS SOMETHING ELSE ....
CAMBRIDGE, MA--(Marketwired - Oct 24, 2013) - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report third quarter financial results before the NASDAQ Global Market opens on Tuesday, November 12, 2013. Subsequently, at 8:00 a.m., Eastern Time (5:00 a.m., Pacific Time), Chris Garabedian, Sarepta's president and chief executive officer, and Sandy Mahatme, Sarepta's chief financial officer, will host a conference call to discuss third quarter financial results and to provide a corporate update.
pharma-s...............................................................................................................................................................look at gild for the last 2 days and that is a great stock